Shield Therapeutics plc (LON:STX – Get Free Report) rose 12.4% on Wednesday. The stock traded as high as GBX 3.50 and last traded at GBX 3.43. Approximately 19,767,809 shares were traded during mid-day trading, an increase of 687% from the average session volume of 2,511,357 shares. The stock had previously closed at GBX 3.05.
Shield Therapeutics Price Performance
The company has a fifty day moving average of GBX 5.25 and a 200-day moving average of GBX 6.96. The firm has a market cap of £36.82 million, a P/E ratio of -3.43 and a beta of 1.77. The company has a debt-to-equity ratio of -146.28, a current ratio of 0.75 and a quick ratio of 2.16.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
